PCOS Is Now PMOS: Lab Tests and Hormone Guide

Polycystic ovary syndrome (PCOS) is now called polyendocrine metabolic ovarian syndrome (PMOS). There is still no single “PCOS hormone panel” or PMOS blood test. In adults, diagnosis uses a combination of ovulatory dysfunction, clinical or biochemical androgen excess, and ovarian morphology, after other explanations are excluded. Laboratory tests can contribute to that assessment and to metabolic risk review, but no result diagnoses PMOS by itself.

This guide is a test-purpose map. It explains why a clinician may choose a test, what the result cannot decide, and which source details make the record safer to review. It is not a list to self-order and does not supply personal targets, medication advice, fertility advice, or a retesting schedule.

PCOS is now PMOS—and the evidence did not reset

The international consortium changed the name from PCOS to PMOS on May 12, 2026. The change recognizes that the condition is not defined by abnormal ovarian cysts and has endocrine, metabolic, ovarian, dermatologic, and psychological dimensions. The Monash University name-change announcement describes a three-year terminology transition, with full implementation planned for the 2028 international guideline update.

You will still see PCOS in older records, portals, research papers, billing systems, and search results. In this article, PCOS and PMOS refer to the same condition. The June 2026 international PMOS guideline PDF is the 2023 evidence-based guideline updated to use the new name; it is not a new evidence review that replaced the 2023 recommendations.

What counts toward an adult PMOS diagnosis?

The international guideline retains the adult framework often called the modified Rotterdam criteria. After other relevant causes have been excluded, an adult may be diagnosed when at least two of three features are present:

• Ovulatory dysfunction. Irregular or absent ovulation is usually assessed from cycle history. Regular bleeding does not always prove ovulation, and a clinician may select progesterone testing when confirmation is needed.
• Clinical or biochemical hyperandrogenism. Clinical evidence can include signs such as hirsutism. Biochemical evidence comes from carefully selected androgen measurements.
• Polycystic ovary morphology (PCOM). In adults, ultrasound or anti-Müllerian hormone (AMH) may contribute evidence of PCOM in the diagnostic algorithm.

If irregular cycles and hyperandrogenism already supply two criteria, the guideline says ultrasound is not necessary and AMH is not necessary. AMH is not a stand-alone PMOS test, and using AMH and ultrasound together just to confirm the same morphology feature can increase overdiagnosis. The ovaries do not need to contain abnormal “cysts” for the condition to exist.

Which blood tests answer which questions?

The ARUP Consult laboratory guide organizes testing by purpose: biochemical hyperandrogenism, exclusion of other conditions, ovulatory evidence when needed, and PCOM evidence when needed. That structure is more accurate than calling every analyte part of one standard panel.

Androgen tests contribute diagnostic evidence

For biochemical hyperandrogenism, current guidance starts with total and free testosterone. Free testosterone may be estimated with a calculated free androgen index, or assessed with validated calculation or laboratory methods. The result still needs the report's reference interval and clinical context; it is not a universal cutoff. The testosterone guide explains why the exact analyte, unit, assay, and comparison matter.

Method is especially important at the concentrations commonly measured in this setting. The guideline prefers validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) for total testosterone over direct immunoassays, which have limited sensitivity and precision for this purpose. The CDC hormone standardization program also uses HPLC–MS/MS reference methods to assess the analytical accuracy of routine testosterone and estradiol tests.

If total and free testosterone are not elevated, a clinician may consider androstenedione and DHEA-S, with the important limits that they are less specific and DHEA-S declines with age. DHEA-S can add androgen evidence; one value does not reliably locate a cause in the adrenal glands versus the ovaries. See the separate DHEA-S guide for its age, assay, and source-report boundaries.

Estradiol, LH, FSH, SHBG, and other hormones may answer selected questions, but they are not universal PMOS diagnostic-panel requirements. In particular, an LH-to-FSH ratio is not one of the three diagnostic criteria. SHBG may be used in a free-androgen calculation, yet it is also affected by hormonal medicines and other context.

Combined oral contraceptive pills can change SHBG and androgen production, making biochemical androgen assessment difficult. Do not stop contraception or any prescribed medicine because of an online guide. Preserve the exact product, dose, dates, and reason for use, then ask the ordering clinician how that context affects the question and the plan.

Exclusion tests look for other explanations

PMOS is a diagnosis of exclusion. The international and ARUP guidance identify thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia as core alternative explanations to assess. Common laboratory routes are TSH, prolactin, and 17-hydroxyprogesterone, respectively.

That does not make those three results a do-it-yourself rule-out panel. The history and clinical picture can call for other selected evaluation, including questions about hypothalamic or pituitary function, ovarian insufficiency, Cushing syndrome, medicine effects, or an androgen-secreting condition. A normal TSH, prolactin, or 17-hydroxyprogesterone result answers its own question; it does not prove PMOS.

Marked androgen results, or new, severe, or rapidly progressing androgen-related signs, can have causes other than PMOS. The guideline emphasizes both the laboratory comparison and the timing of symptom onset. Those patterns need clinician evaluation, not a self-triage cutoff copied from another laboratory.

Metabolic tests assess health risk, not the diagnosis alone

PMOS has important metabolic dimensions, but a glucose result is not one of the three adult diagnostic criteria. The international guideline recommends glycemic assessment for adults and adolescents with PMOS regardless of BMI and calls a 75-gram oral glucose tolerance test (OGTT) the most accurate available test for glycemic status in PMOS. If an OGTT cannot be performed, fasting plasma glucose and/or HbA1c can be considered with lower accuracy for this purpose.

The NIDDK diabetes testing guide explains the practical difference: an OGTT measures the response after a glucose drink, fasting plasma glucose is a single fasting measurement, and HbA1c reflects longer-term glycemia but can be unreliable in some circumstances. These tests are not interchangeable labels.

The guideline also includes a lipid profile and blood-pressure assessment in cardiometabolic review. Follow-up frequency belongs to an individualized plan based on prior results and other risk factors. It specifically says clinically available insulin assays have limited relevance in routine care and does not recommend them as routine PMOS assessment. “Fasting insulin” therefore should not be treated as a required item or a universal insulin-resistance score.

Adolescence and menopause need different boundaries

Adolescents

Normal pubertal development can resemble parts of adult PMOS criteria. After other explanations are excluded, the international guideline requires both ovulatory dysfunction and clinical or biochemical hyperandrogenism for an adolescent diagnosis. Ultrasound and AMH should not be used to diagnose PMOS in adolescents. A young person with some features but not both may be described as at increased risk by a clinician rather than prematurely labeled from one test.

Perimenopause and postmenopause

Cycle patterns, hormone concentrations, and ovarian morphology change across menopause, so a new hormone panel cannot simply reapply reproductive-age criteria. The guideline says PMOS can be considered enduring, and a postmenopausal assessment may rely on a past diagnosis or a long-term earlier history of irregular cycles plus hyperandrogenism and/or PCOM. New, severe, or worsening hyperandrogenism after menopause calls for evaluation of other causes. The perimenopause and menopause labs guide explains why life stage must stay attached to the record.

What a hormone panel cannot decide about treatment

A PMOS workup does not create a single biochemical target that every treatment should “normalize.” Management decisions can address different concerns—such as symptoms, cycle management, metabolic health, emotional wellbeing, or reproductive goals—and the evidence and tradeoffs differ for each. This article does not recommend a medicine, supplement, diet, fertility intervention, or target.

The international guideline also says repeated androgen measurements have a limited role in ongoing adult assessment. A lower androgen value does not by itself prove that a treatment improved health, and a stable value does not show that symptoms or risks are unchanged. Metabolic follow-up is a separate clinical question. Ask which outcome is being followed and what evidence would change the plan instead of treating the whole panel as one score.

The useful question is not “Did every hormone move toward an optimal number?” It is “What job was this test meant to do, and what does the complete evidence support?”

A five-step PMOS lab-record workflow

1. Define the clinical question

Label each result by its intended job: diagnostic evidence, exclusion of another explanation, confirmation of ovulation when needed, or metabolic health assessment. If the purpose is unclear, record that as a question rather than assuming every item belongs to a standard panel.

2. Preserve each source report

Keep the exact test name, value, unit, flag, report interval, laboratory, collection date, specimen, and any assay, calculation, or sample note. A copied “testosterone: high” strips away facts needed to review the result safely. Use the report's comparison and the guide to understanding lab reference ranges, not an online optimal target.

3. Record interpretation context

Attach life stage, cycle history, symptoms and their timing, why the test was ordered, relevant diagnoses, and prescribed or nonprescribed medicines and hormones. Record changes accurately without deciding that one caused the result, and do not change treatment to make a future panel easier to interpret.

4. Keep test purposes separate

Group androgen evidence, exclusion tests, and metabolic assessment into separate lanes. Before describing a change over time, compare analyte, unit, interval, laboratory, method, and collection context. The guide to combining results from different labs shows how to preserve uncertain comparability rather than silently normalizing it.

5. Prepare bounded questions

Useful questions for the ordering clinician include:

• Which diagnostic criterion or alternative explanation is this test addressing?
• Is the testosterone method appropriate for the concentration and question?
• How do hormonal medicines, life stage, and symptom timing affect this review?
• Is a morphology test actually needed, and if so, why this method?
• Which metabolic test fits the clinical question, and what are its limitations?
• What outcome is being followed, and what evidence would change the plan?

A source-aware record summary

A careful summary could read: “Evaluation documented under the former PCOS and current PMOS names. Cycle history and symptom timing preserved. Total and free testosterone reports include units, intervals, laboratory, method, and medicine context. TSH, prolactin, and 17-hydroxyprogesterone are labeled as exclusion tests; glucose and lipid results are labeled metabolic assessment. Diagnostic conclusion and follow-up remain with the clinician.”

That summary is useful because it keeps evidence and uncertainty visible. It does not count criteria on the reader's behalf, claim that another condition was excluded, or convert a laboratory flag into a treatment instruction.

Where Libby fits

Libby can help organize source reports, dates, exact values, units, report intervals, and context notes in one record. It does not determine whether two methods are comparable, decide which tests should be ordered, diagnose PMOS, exclude another condition, interpret urgency, or recommend treatment or fertility care.

Use the organized record to prepare the bounded questions above. If that would reduce record-chasing before a visit, you can start your record with the CTA below.

FAQ

Is PCOS really called PMOS now? Yes. The international consortium changed the name to polyendocrine metabolic ovarian syndrome, or PMOS, on May 12, 2026. A three-year transition means PCOS will remain common in records and searches; both names refer to the same condition.

Can a blood test diagnose PMOS or PCOS? No single blood test can. Adult diagnosis combines at least two of three features—ovulatory dysfunction, hyperandrogenism, and PCOM—after other relevant explanations are excluded. The clinician integrates history, examination, selected labs, and sometimes morphology evidence.

Which hormone tests are used first for biochemical hyperandrogenism? Current international guidance starts with total and free testosterone. It prefers LC-MS/MS for total testosterone and validated calculation or laboratory methods for free testosterone. DHEA-S and androstenedione may be considered later and are less specific.

Can AMH diagnose PMOS by itself? No. In adults, AMH may be used within the diagnostic algorithm as an alternative to ultrasound for PCOM when that criterion is needed. It is not a stand-alone test, is not needed when two other adult criteria are met, and is not recommended for adolescent diagnosis.

Should fasting insulin be in every PMOS panel? No. The international guideline says routine clinically available insulin assays have limited relevance and are not recommended in routine care. Glycemic assessment is important, but OGTT, fasting plasma glucose, and HbA1c answer different questions and are not equally accurate for PMOS.

Can hormonal birth control affect androgen results? Yes. Combined oral contraceptives can increase SHBG and reduce gonadotropin-dependent androgen production, making biochemical assessment difficult. Do not stop a prescribed contraceptive because of this article; record the product and dates and ask the clinician how it affects the plan.

Are adult diagnostic criteria used for adolescents? Not unchanged. After excluding other causes, adolescents need both ovulatory dysfunction and hyperandrogenism. Ultrasound and AMH are not recommended for adolescent diagnosis because normal pubertal development can overlap with adult features.

Can PMOS be diagnosed after menopause? It may be considered after menopause from a past diagnosis or a long-term reproductive-age history, but a new panel cannot simply recreate that history. New, severe, or worsening androgen-related signs after menopause need evaluation for other causes.

References

• International Evidence-Based Guideline for PMOS, updated terminology edition — Monash University
• PCOS Is Now PMOS: Understanding the Name Change — American Society for Reproductive Medicine
• Polyendocrine Metabolic Ovarian Syndrome: New Name and Transition — Monash University
• Recommendations From the 2023 International Evidence-Based Guideline — Human Reproduction
• Polycystic Ovary Syndrome: Choose the Right Test — ARUP Consult
• Steroid Hormones Standardization Programs — CDC
• Diabetes Tests and Diagnosis — NIDDK
• PMOS Guideline Project Information — NICE